Last updated Saturday, 28 March 2009

CANCER WORKSHOP – Program

Friday, 13 October 2006
14:00 – 18:00 Registration/Poster Set-up
18:00 – 21:00 Opening Reception followed by Dinner
Saturday, 14 October 2006
07:00 Registration opens
07:30 Breakfast
08:30 Opening Remarks
  Oral Session 1: Metabolic Assessment of Cancer Using C13 Imaging and Spectroscopy, Martin Leach, Ph.D., Chair
08:45 Magnetic Resonance Probing of Cancer Metabolism and Physiology
Hadassa Degani, Ph.D., Weizmann Institute of Science, Rehovot, Israel
09:30 Preclinical Hyperpolarized C-13 MRSI Studies of Prostate Cancer - not available
Daniel B. Vigneron, Ph.D., University of California, San Francisco, CA, USA
10:00 Break
 

Oral Session 2: Tumor models - MRI and the Microenvironment I, Simon Robinson, Ph.D., Chair
10:30 Imag(in)ing the Tumor Microenvironment
Robert J. Gillies, Ph.D., University of Arizona, Tucson, AZ, USA
 

Proffered Papers
10:55 Quantification of liver tumor necrotic fraction using diffusion-weighted PROPELLER MRI in the VX2 rabbit model
Jie Deng. M.Sc., Northwestern University, Chicago, IL, USA
11:10 The simultaneous measurement of blood flow, blood volume and Ktrans using DSC-MRI
Christopher C. Quarles, Ph.D., Vanderbilt University, Nashville, TN, USA
11:25 Multi-parametric MRI/MRSI/DTI and T2-relaxometry imaging of prostate cancer at 3T
Daniel B. Vigneron, Ph.D., University of California San Francisco, CA, USA
11:40 Tumour response to 5,6-dimethylxanthenone-4-acetic acid (DMXAA) assessed by intrinsic-susceptibility MRI
Lesley D. McPhail. B.Sc., St. George’s Hospital Medical School, London, UK     
11:55 Lunch
14:00 Poster Session 1: Clinical Assessment of Human Cancer with MRI and MRS (Odd-Numbered Posters)
15:30 Fourth Negendank Memorial Lecture, Jeffrey Evelhoch, Ph.D. Chair
To Image and Imagine: MR Molecular-Functional Imaging (MFI) of Cancer
Zaver Bhujwalla, Ph.D., Johns Hopkins University, Baltimore, MD, USA
16:15 Break
  Oral Session 3: Tumor models - MRI and the Microenvironment II, Jeff Evelhoch, Ph.D., Chair
16:30

Characterizing “Angiogenic” Contrast And Extracellular Matrix Integrity In Tumors Using MRI
Arvind P. Pathak, Ph.D., Johns Hopkins University, Baltimore, MD, USA
  Proffered Papers
16:55

Inhibition of tumor growth and angiogenesis by a novel dual EGF-R and VEGF-R inhibitor in mouse xenograft model: a DCE-MRI study
Natalie J. Serkova, Ph.D., University of Colorado Health Services, Denver, CO, USA
17:10 Characterization of prostate cancer xenografts in orthotopic and subcutaneous sites
Marie-France Penet, Ph.D., Johns Hopkins University, Baltimore, MD, USA
17:25 Prediction of human melanoma metastatic potential in mouse xenografts by MR and optical imaging
Lin Li,Ph.D., University of Pennsylvania, Philadelphia, PA, USA
18:30 Dinner
Sunday, 15 October 2006
07:30 Breakfast
  Oral Session 4: Clinical Translation of MRI, Thomas L. Chenevert, Ph.D., Chair
08:30 New Frontiers in Oncologic Imaging: Where are the Opportunities and Challenges?
Michael V. Knopp, M.D., Ohio State University, Columbus, OH, USA
08:55 Clinical Translation of MRI in Cancer
Yael Mardor, Ph.D., Sheba Medical Center, Tel-Hashomer, Israel
  Proffered Papers
09:20 Multiparametric MR studies for monitoring treatment response of head and neck cancers
Sungheon Kim, Ph.D., University of Pennsylvania, Philadelphia, PA, USA
09:35 Voxel-based analysis of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation
Wilburn E. Reddick, Ph.D., St. Jude Children’s Research Hospital, Memphis, TN, USA
09:50 Break
  Oral Session 5: Targeted Contrast Agents – Molecular Imaging, Edward J. Delikatny, Ph.D., Chair
10:10 Towards MRI Agents that Report Biological Functions
A. Dean Sherry, Ph.D., University of Texas, Dallas, TX, USA
10:35 Molecular Imaging Probes For Cancer Detection and Therapy Assessment
Anna V. Moore, Ph.D., Harvard Medical School, Charlestown, MA, USA
10:55 Targeted Contrast Agents
Dimitri Artemov, Ph.D., Johns Hopkins University, Baltimore, MD, USA
  Proffered Papers
11:25 Amide proton transfer (APT) imaging of human brain tumors: A comparison with conventional MT imaging
Jinyuan Zhou, Ph.D., Johns Hopkins University, Baltimore MD, USA
11:40 uPAR-targeted iron oxide nanoparticles for in vivo MRI of breast cancer
Xianghong Peng, Emory University School of Medicine, Atlanta, GA, USA
11:55 Lunch
13:45 Poster Session 2: Cell and Animal Models of Cancer (Even-Numbered Posters)
  Oral Session 6: Cell Imaging, Spectroscopy and Tracking, Harish Poptani, Ph.D., Chair
15:15 Imaging Tumour Responses to Therapy
Kevin Brindle, Ph.D., University of Cambridge, Cambridge, England, UK
15:40 Labeling and In-Vivo Tracking of Natural Killer Cells To Tumors - not available
Heike Daldrup-Link, University of California, San Francisco, CA, USA
16:05 Break
  Proffered Papers
16:20

Monitoring the fate of metastatic breast cancer in vivo in the mouse brain
Chris Heyn, Robarts Research Institute, London, ON, Canada   

16:35 Detecting single iron labeled cancer cells in mouse brain: Comparison of FIESTA imaging protocols at 1.5 and 3.0 Tesla
Soha Ramadan, B.M.Sc., University of Western Ontario, London, ON, Canada
  Special Session:  Potentials and Pitfalls of Molecular Imaging in Cancer
16:50 Molecular Imaging, Alnawaz Rehemtulla, Ph.D., MSC, University of Michigan, Ann Arbor, MI, USA
17:35 Roundtable Discussion, Michael Garwood, Ph.D., Moderator
18:30 Dinner
Monday, 16 October 2006
07:30 Breakfast
  Oral session 7: Clinical Translation of MRS, Jeffry Alger, Ph.D., Chair
09:00 MR Spectroscopy in Clinical Oncology
Arend Heerschap, Ph.D., Radboud University, Nijmegen, The Netherlands
09:25 MR Spectroscopy of the Breast
Patrick J. Bolan, University of Minnesota, Minneapolis MN, USA
  Proffered Papers
09:50 Arterial spin labeling and magnetic resonance spectroscopy in differentiation of gliomas
Sanjeev Chawla,, M.Sc., University of Pennsylvania, Philadelphia, PA, USA
10:05 Fast non-invasive 3D proton-MR spectroscopic imaging of the human prostate at 3 Tesla without an endorectal coil
Tom Scheenen, Ph.D., Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
10:25 MR determined metabolic phenotype predicts apoptosis in treatment of cervical carcinomas
Tone F. Bathen, Ph.D., NTNU, Trondheim, Norway
10:40 Break
  Oral Session 8: Tumor Models/MRS and Metabolism, Jerry Glickson, Ph.D., Chair
11:00 Alterations of Choline Phospholipid Metabolism in a Model Of Epithelial Ovarian Tumor Progression
Franca Podo, D.Sc., Istituto Superiore di Sanitá, Rome, Italy
11:25 MRS In The Evaluation Of Molecularly Targeted Cancer Therapeutics - not available
Mounia Beloueche-Babari, Ph.D., Royal Marsden Hospital, Sutton, Surrey, England, UK
  Proffered Papers
11:50 siRNA-mediated choline kinase suppression sensitizes breast cancer cells to 5-fluorouracil treatment
Kristine Glunde, Ph.D., Johns Hopkins University, Baltimore, MD, USA
12:05 The PPAR-γ inhibitor GW9662 attenuates phenylbutyrate-induced lipid metabolite accumulation in DU145 prostate cancer cells
Matthew Milkevitch, Ph.D., University of Pennsylvania, Philadelphia, PA, USA
12:20 Phosphocholine levels are modulated downstream of MAPK and PI3K signaling via inhibition of fatty acid synthase
James Ross, Ph.D. M.D., Anderson Cancer Center, Houston, TX, USA
12:35 Closing Remarks
12:45 Box Lunch

The International Society for Magnetic Resonance in Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.